USP33-mediated stabilization of c-Myc drives glycolytic reprogramming and promotes ovarian cancer progression
Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of effective early diagnostic markers. Recent evidence suggests that deubiquitinating enzymes (DUBs) play pivotal roles in tumor development and metab...
Gespeichert in:
| Veröffentlicht in: | Biochimica et biophysica acta. General subjects Jg. 1869; H. 9; S. 130830 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
Elsevier B.V
01.08.2025
|
| Schlagworte: | |
| ISSN: | 0304-4165, 1872-8006, 1872-8006 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of effective early diagnostic markers. Recent evidence suggests that deubiquitinating enzymes (DUBs) play pivotal roles in tumor development and metabolic reprogramming. Here, we identify and characterize the function of the deubiquitinase USP33 in regulating c-Myc stability and glycolytic metabolism in OC. Through quantitative PCR (qPCR) and Western blot analyses, we show that USP33 is significantly upregulated in both OC tissues and cell lines compared to normal controls. Functional assays reveal that USP33 knockdown markedly inhibits cell proliferation, migration, and invasion while promoting apoptosis. Metabolically, USP33 silencing reduces glucose uptake, lactate production, and the extracellular acidification rate, consistent with downregulation of key glycolytic enzymes (LDHA, GLUT1, and PKM2). Mechanistically, co-immunoprecipitation and ubiquitination assays demonstrate that USP33 interacts with and deubiquitinates c-Myc at K48-linked chains, thereby stabilizing c-Myc protein levels and enhancing its transcriptional activity. Moreover, c-Myc overexpression rescues the inhibitory effects of USP33 knockdown on both glycolysis and malignant phenotypes. Clinically, high USP33 expression correlates with poor prognosis, suggesting that the USP33–c-Myc axis may serve as both a prognostic biomarker and a potential therapeutic target. Taken together, our findings highlight a critical role for USP33 in OC pathogenesis by mediating c-Myc-driven glycolytic reprogramming, and they provide new insights for developing targeted treatment strategies aimed at disrupting this pathway.
•USP33 is upregulated in ovarian cancer: Significantly higher expression is observed in tumor tissues and cell lines compared to normal controls.•Promotes malignancy: USP33 knockdown inhibits proliferation, migration, and invasion while inducing apoptosis.•Enhances glycolysis: USP33 stabilizes c-Myc, upregulating glycolytic enzymes (LDHA, GLUT1, PKM2) to increase glycolytic flux.•Deubiquitinates c-Myc: Removes K48-linked ubiquitin chains, preventing degradation and enhancing transcriptional activity.•Clinical relevance: High USP33 levels predict poor prognosis, indicating USP33/c-Myc as a potential therapeutic and diagnostic target. |
|---|---|
| AbstractList | Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of effective early diagnostic markers. Recent evidence suggests that deubiquitinating enzymes (DUBs) play pivotal roles in tumor development and metabolic reprogramming. Here, we identify and characterize the function of the deubiquitinase USP33 in regulating c-Myc stability and glycolytic metabolism in OC. Through quantitative PCR (qPCR) and Western blot analyses, we show that USP33 is significantly upregulated in both OC tissues and cell lines compared to normal controls. Functional assays reveal that USP33 knockdown markedly inhibits cell proliferation, migration, and invasion while promoting apoptosis. Metabolically, USP33 silencing reduces glucose uptake, lactate production, and the extracellular acidification rate, consistent with downregulation of key glycolytic enzymes (LDHA, GLUT1, and PKM2). Mechanistically, co-immunoprecipitation and ubiquitination assays demonstrate that USP33 interacts with and deubiquitinates c-Myc at K48-linked chains, thereby stabilizing c-Myc protein levels and enhancing its transcriptional activity. Moreover, c-Myc overexpression rescues the inhibitory effects of USP33 knockdown on both glycolysis and malignant phenotypes. Clinically, high USP33 expression correlates with poor prognosis, suggesting that the USP33–c-Myc axis may serve as both a prognostic biomarker and a potential therapeutic target. Taken together, our findings highlight a critical role for USP33 in OC pathogenesis by mediating c-Myc-driven glycolytic reprogramming, and they provide new insights for developing targeted treatment strategies aimed at disrupting this pathway.
•USP33 is upregulated in ovarian cancer: Significantly higher expression is observed in tumor tissues and cell lines compared to normal controls.•Promotes malignancy: USP33 knockdown inhibits proliferation, migration, and invasion while inducing apoptosis.•Enhances glycolysis: USP33 stabilizes c-Myc, upregulating glycolytic enzymes (LDHA, GLUT1, PKM2) to increase glycolytic flux.•Deubiquitinates c-Myc: Removes K48-linked ubiquitin chains, preventing degradation and enhancing transcriptional activity.•Clinical relevance: High USP33 levels predict poor prognosis, indicating USP33/c-Myc as a potential therapeutic and diagnostic target. Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of effective early diagnostic markers. Recent evidence suggests that deubiquitinating enzymes (DUBs) play pivotal roles in tumor development and metabolic reprogramming. Here, we identify and characterize the function of the deubiquitinase USP33 in regulating c-Myc stability and glycolytic metabolism in OC. Through quantitative PCR (qPCR) and Western blot analyses, we show that USP33 is significantly upregulated in both OC tissues and cell lines compared to normal controls. Functional assays reveal that USP33 knockdown markedly inhibits cell proliferation, migration, and invasion while promoting apoptosis. Metabolically, USP33 silencing reduces glucose uptake, lactate production, and the extracellular acidification rate, consistent with downregulation of key glycolytic enzymes (LDHA, GLUT1, and PKM2). Mechanistically, co-immunoprecipitation and ubiquitination assays demonstrate that USP33 interacts with and deubiquitinates c-Myc at K48-linked chains, thereby stabilizing c-Myc protein levels and enhancing its transcriptional activity. Moreover, c-Myc overexpression rescues the inhibitory effects of USP33 knockdown on both glycolysis and malignant phenotypes. Clinically, high USP33 expression correlates with poor prognosis, suggesting that the USP33-c-Myc axis may serve as both a prognostic biomarker and a potential therapeutic target. Taken together, our findings highlight a critical role for USP33 in OC pathogenesis by mediating c-Myc-driven glycolytic reprogramming, and they provide new insights for developing targeted treatment strategies aimed at disrupting this pathway.Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of effective early diagnostic markers. Recent evidence suggests that deubiquitinating enzymes (DUBs) play pivotal roles in tumor development and metabolic reprogramming. Here, we identify and characterize the function of the deubiquitinase USP33 in regulating c-Myc stability and glycolytic metabolism in OC. Through quantitative PCR (qPCR) and Western blot analyses, we show that USP33 is significantly upregulated in both OC tissues and cell lines compared to normal controls. Functional assays reveal that USP33 knockdown markedly inhibits cell proliferation, migration, and invasion while promoting apoptosis. Metabolically, USP33 silencing reduces glucose uptake, lactate production, and the extracellular acidification rate, consistent with downregulation of key glycolytic enzymes (LDHA, GLUT1, and PKM2). Mechanistically, co-immunoprecipitation and ubiquitination assays demonstrate that USP33 interacts with and deubiquitinates c-Myc at K48-linked chains, thereby stabilizing c-Myc protein levels and enhancing its transcriptional activity. Moreover, c-Myc overexpression rescues the inhibitory effects of USP33 knockdown on both glycolysis and malignant phenotypes. Clinically, high USP33 expression correlates with poor prognosis, suggesting that the USP33-c-Myc axis may serve as both a prognostic biomarker and a potential therapeutic target. Taken together, our findings highlight a critical role for USP33 in OC pathogenesis by mediating c-Myc-driven glycolytic reprogramming, and they provide new insights for developing targeted treatment strategies aimed at disrupting this pathway. Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of effective early diagnostic markers. Recent evidence suggests that deubiquitinating enzymes (DUBs) play pivotal roles in tumor development and metabolic reprogramming. Here, we identify and characterize the function of the deubiquitinase USP33 in regulating c-Myc stability and glycolytic metabolism in OC. Through quantitative PCR (qPCR) and Western blot analyses, we show that USP33 is significantly upregulated in both OC tissues and cell lines compared to normal controls. Functional assays reveal that USP33 knockdown markedly inhibits cell proliferation, migration, and invasion while promoting apoptosis. Metabolically, USP33 silencing reduces glucose uptake, lactate production, and the extracellular acidification rate, consistent with downregulation of key glycolytic enzymes (LDHA, GLUT1, and PKM2). Mechanistically, co-immunoprecipitation and ubiquitination assays demonstrate that USP33 interacts with and deubiquitinates c-Myc at K48-linked chains, thereby stabilizing c-Myc protein levels and enhancing its transcriptional activity. Moreover, c-Myc overexpression rescues the inhibitory effects of USP33 knockdown on both glycolysis and malignant phenotypes. Clinically, high USP33 expression correlates with poor prognosis, suggesting that the USP33-c-Myc axis may serve as both a prognostic biomarker and a potential therapeutic target. Taken together, our findings highlight a critical role for USP33 in OC pathogenesis by mediating c-Myc-driven glycolytic reprogramming, and they provide new insights for developing targeted treatment strategies aimed at disrupting this pathway. |
| ArticleNumber | 130830 |
| Author | Liu, Yiming Zhang, Xiaobo Zhao, Yue Shi, Xiaocheng Chen, Dejia Lou, Ge |
| Author_xml | – sequence: 1 givenname: Dejia surname: Chen fullname: Chen, Dejia organization: Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China – sequence: 2 givenname: Yue surname: Zhao fullname: Zhao, Yue organization: Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China – sequence: 3 givenname: Xiaobo surname: Zhang fullname: Zhang, Xiaobo organization: Gynecology Research Institute, School of Health and Nursing, Guangzhou Huali College, No. 1 Huali Road, Zhucun Sub-district, Zengcheng District, Guangzhou 511370, Guangdong Province, P.R. China – sequence: 4 givenname: Xiaocheng surname: Shi fullname: Shi, Xiaocheng organization: Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China – sequence: 5 givenname: Yiming surname: Liu fullname: Liu, Yiming organization: Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China – sequence: 6 givenname: Ge surname: Lou fullname: Lou, Ge email: louge@ems.hrbmu.edu.cn organization: Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40532745$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kVtrGzEQhUVxaJzLPwhBj31ZR9Ks9vJSKKY3cEggybPQSrNGZldKpbXB-fVVum4fOy_DwDdnmHMuyMIHj4TccLbijFd3u1XX6S36lWBCrjiwBtgHsuRNLYqGsWpBlgxYWZS8kufkIqUdyyVb-ZGcl0yCqEu5JOPL0yNAMaJ1ekJL06Q7N7g3PbngaeipKe6PhtroDpjodjiaMBwnZ2jE1xi2UY-j81uqvaV5HsOUqXDQ0WlPjfYGI_3DYUpZ8Iqc9XpIeH3ql-Tl29fn9Y9i8_D95_rLpjDAYSoazdGC6EAaENp2UjMjW6FrabsKwbKqqXowDe-bOrN9WbcdL3vRs1pCnuCSfJp18-1fe0yTGl0yOAzaY9gnBUIIkBLaNqO3J3TfZRfUa3Sjjkf116IMlDNgYkgpYv8P4Uy9J6F2ak5CvSeh5iTy2ud5DfOfB4dRJeMwG2JdRDMpG9z_BX4DMzqTkg |
| Cites_doi | 10.3390/ijms231912041 10.1038/s41388-024-03151-9 10.1073/pnas.0801262106 10.1038/s41392-021-00562-y 10.1016/j.bbagrm.2023.194979 10.1080/15548627.2015.1042195 10.1038/nm.3739 10.3389/fimmu.2023.1189953 10.3390/ijms22094546 10.1038/s41419-020-2336-0 10.1186/s12885-024-12009-y 10.1016/j.molcel.2023.02.022 10.1007/978-1-4615-2592-9_12 10.7150/ijbs.100355 10.1073/pnas.2209435120 10.1159/000479006 10.1038/s41420-023-01629-1 10.1159/000494238 10.7150/ijbs.69411 10.6004/jnccn.2022.0047 10.1126/sciadv.abo0987 10.1002/cac2.12351 10.1016/j.ctrv.2021.102154 10.1002/glia.24482 10.1016/j.pharmthera.2023.108413 10.3389/fimmu.2020.577869 10.3389/fimmu.2023.1284853 10.1158/1541-7786.MCR-23-0962 10.1080/15548627.2019.1656957 10.1007/BF01753886 10.1038/s41571-024-00881-3 10.1002/cbin.12024 10.1146/annurev.pathol.4.110807.092246 10.1016/j.tcb.2022.07.006 10.1038/s41419-023-05871-4 10.1038/s41467-019-11662-3 10.1016/j.lfs.2022.120322 10.1038/s41418-020-00648-0 10.1042/BST0370937 10.1016/j.drup.2018.03.001 10.1111/cpr.12606 |
| ContentType | Journal Article |
| Copyright | 2024 Copyright © 2024. Published by Elsevier B.V. Copyright © 2025. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2024 – notice: Copyright © 2024. Published by Elsevier B.V. – notice: Copyright © 2025. Published by Elsevier B.V. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.bbagen.2025.130830 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Biology |
| EISSN | 1872-8006 |
| ExternalDocumentID | 40532745 10_1016_j_bbagen_2025_130830 S0304416525000753 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABEFU ABFNM ABGSF ABMAC ABUDA ABWVN ABXDB ACDAQ ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AEUPX AFJKZ AFPUW AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CS3 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HLW HVGLF HZ~ IHE J1W KOM LX3 M41 MO0 N9A O-L O9- OAUVE OHT OZT P-8 P-9 PC. Q38 R2- ROL RPZ SBG SCC SDF SDG SDP SES SEW SPCBC SSU SSZ T5K UQL WH7 WUQ XJT XPP ~G- 9DU AAYXX ACLOT CITATION EFLBG ~HD AGRNS BNPGV CGR CUY CVF ECM EIF NPM SSH 7X8 |
| ID | FETCH-LOGICAL-c313t-8a1ed32b35c32adb5a0c592a75db6e3d0686f3c81f878a1f479b14f2f0753f473 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001520808800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0304-4165 1872-8006 |
| IngestDate | Thu Oct 02 22:34:04 EDT 2025 Wed Jul 23 01:47:39 EDT 2025 Sat Nov 29 07:44:34 EST 2025 Sat Aug 16 17:00:56 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | C-Myc Glycolysis SP33 Metabolic reprogramming Deubiquitination Ovarian cancer |
| Language | English |
| License | Copyright © 2024. Published by Elsevier B.V. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c313t-8a1ed32b35c32adb5a0c592a75db6e3d0686f3c81f878a1f479b14f2f0753f473 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 40532745 |
| PQID | 3222355399 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3222355399 pubmed_primary_40532745 crossref_primary_10_1016_j_bbagen_2025_130830 elsevier_sciencedirect_doi_10_1016_j_bbagen_2025_130830 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-08-01 |
| PublicationDateYYYYMMDD | 2025-08-01 |
| PublicationDate_xml | – month: 08 year: 2025 text: 2025-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Biochimica et biophysica acta. General subjects |
| PublicationTitleAlternate | Biochim Biophys Acta Gen Subj |
| PublicationYear | 2025 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Konstantinopoulos, Matulonis (bb0145) 2023; 4 Dang, Nie, Wei (bb0045) 2021; 28 Das, Lewis, Levens (bb0240) 2023; 33 Armstrong (bb0015) 2022; 20 Lin (bb0215) 2023; 14 Cao (bb0220) 2020; 11 Zhang (bb0225) 2024; 24 Duffy (bb0235) 2021; 94 Wang (bb0200) 2024; 72 Yang (bb0030) 2020; 11 Tao (bb0060) 2024; 22 Cho, Shih (bb0140) 2009; 4 Zhou (bb0230) 2023; 13 Liu (bb0125) 2023; 14 Li (bb0070) 2023; 9 Zhang (bb0025) 2022; 23 Xie (bb0095) 2022; 292 Xia (bb0165) 2019; 52 Komander (bb0160) 2009; 37 Popovic, Vucic, Dikic (bb0035) 2014; 20 Thompson (bb0175) 1994; 12 Webb, Jordan (bb0010) 2024; 21 Tan, Miyamoto (bb0195) 2015; 11 Yuan (bb0185) 2024; 181 Zhang (bb0075) 2023; 245 Penny (bb0005) 2020; 91 Gao (bb0100) 2022; 8 Popovic, Vucic, Dikic (bb0155) 2014; 20 Savagner (bb0180) 1994; 71 Han (bb0040) 2022; 18 Beretta (bb0065) 2024; 20 Yuasa-Kawada (bb0120) 2009; 106 Niu (bb0245) 2020; 16 Chen, Liu, Zhou (bb0110) 2021; 22 Fang (bb0105) 2019; 10 Kossaï (bb0150) 2018; 85 Zhong (bb0115) 2023; 47 Lu (bb0170) 2018; 50 Wang (bb0210) 2022; 42 Guo (bb0055) 2024; 11 Konstantinopoulos, Matulonis (bb0020) 2023; 4 Chen (bb0130) 2024; 43 Dagar (bb0050) 2023; 1866 Fang, Luo, Lu (bb0205) 2023; 83 Zhou (bb0135) 2023; 13 Icard (bb0090) 2018; 38 Li (bb0080) 2023; 14 Ma (bb0085) 2023; 120 Zhong (bb0190) 2021; 6 Yang (10.1016/j.bbagen.2025.130830_bb0030) 2020; 11 Gao (10.1016/j.bbagen.2025.130830_bb0100) 2022; 8 Fang (10.1016/j.bbagen.2025.130830_bb0205) 2023; 83 Savagner (10.1016/j.bbagen.2025.130830_bb0180) 1994; 71 Webb (10.1016/j.bbagen.2025.130830_bb0010) 2024; 21 Wang (10.1016/j.bbagen.2025.130830_bb0200) 2024; 72 Yuasa-Kawada (10.1016/j.bbagen.2025.130830_bb0120) 2009; 106 Zhong (10.1016/j.bbagen.2025.130830_bb0115) 2023; 47 Zhang (10.1016/j.bbagen.2025.130830_bb0025) 2022; 23 Cao (10.1016/j.bbagen.2025.130830_bb0220) 2020; 11 Dagar (10.1016/j.bbagen.2025.130830_bb0050) 2023; 1866 Chen (10.1016/j.bbagen.2025.130830_bb0110) 2021; 22 Han (10.1016/j.bbagen.2025.130830_bb0040) 2022; 18 Dang (10.1016/j.bbagen.2025.130830_bb0045) 2021; 28 Lu (10.1016/j.bbagen.2025.130830_bb0170) 2018; 50 Lin (10.1016/j.bbagen.2025.130830_bb0215) 2023; 14 Ma (10.1016/j.bbagen.2025.130830_bb0085) 2023; 120 Zhong (10.1016/j.bbagen.2025.130830_bb0190) 2021; 6 Das (10.1016/j.bbagen.2025.130830_bb0240) 2023; 33 Guo (10.1016/j.bbagen.2025.130830_bb0055) 2024; 11 Zhou (10.1016/j.bbagen.2025.130830_bb0230) 2023; 13 Zhang (10.1016/j.bbagen.2025.130830_bb0075) 2023; 245 Chen (10.1016/j.bbagen.2025.130830_bb0130) 2024; 43 Konstantinopoulos (10.1016/j.bbagen.2025.130830_bb0145) 2023; 4 Wang (10.1016/j.bbagen.2025.130830_bb0210) 2022; 42 Icard (10.1016/j.bbagen.2025.130830_bb0090) 2018; 38 Xie (10.1016/j.bbagen.2025.130830_bb0095) 2022; 292 Xia (10.1016/j.bbagen.2025.130830_bb0165) 2019; 52 Popovic (10.1016/j.bbagen.2025.130830_bb0035) 2014; 20 Li (10.1016/j.bbagen.2025.130830_bb0070) 2023; 9 Cho (10.1016/j.bbagen.2025.130830_bb0140) 2009; 4 Thompson (10.1016/j.bbagen.2025.130830_bb0175) 1994; 12 Tao (10.1016/j.bbagen.2025.130830_bb0060) 2024; 22 Komander (10.1016/j.bbagen.2025.130830_bb0160) 2009; 37 Kossaï (10.1016/j.bbagen.2025.130830_bb0150) 2018; 85 Duffy (10.1016/j.bbagen.2025.130830_bb0235) 2021; 94 Beretta (10.1016/j.bbagen.2025.130830_bb0065) 2024; 20 Li (10.1016/j.bbagen.2025.130830_bb0080) 2023; 14 Konstantinopoulos (10.1016/j.bbagen.2025.130830_bb0020) 2023; 4 Yuan (10.1016/j.bbagen.2025.130830_bb0185) 2024; 181 Penny (10.1016/j.bbagen.2025.130830_bb0005) 2020; 91 Zhou (10.1016/j.bbagen.2025.130830_bb0135) 2023; 13 Popovic (10.1016/j.bbagen.2025.130830_bb0155) 2014; 20 Liu (10.1016/j.bbagen.2025.130830_bb0125) 2023; 14 Fang (10.1016/j.bbagen.2025.130830_bb0105) 2019; 10 Armstrong (10.1016/j.bbagen.2025.130830_bb0015) 2022; 20 Niu (10.1016/j.bbagen.2025.130830_bb0245) 2020; 16 Zhang (10.1016/j.bbagen.2025.130830_bb0225) 2024; 24 Tan (10.1016/j.bbagen.2025.130830_bb0195) 2015; 11 |
| References_xml | – volume: 20 start-page: 1242 year: 2014 end-page: 1253 ident: bb0035 article-title: Ubiquitination in disease pathogenesis and treatment publication-title: Nat. Med. – volume: 20 start-page: 972 year: 2022 end-page: 980 ident: bb0015 article-title: NCCN guidelines® insights: ovarian Cancer, version 3.2022 publication-title: J. Natl. Compr. Cancer Netw. – volume: 33 start-page: 235 year: 2023 end-page: 246 ident: bb0240 article-title: MYC: a complex problem publication-title: Trends Cell Biol. – volume: 24 start-page: 237 year: 2024 ident: bb0225 article-title: USP14 exhibits high expression levels in hepatocellular carcinoma and plays a crucial role in promoting the growth of liver cancer cells through the HK2/AKT/P62 axis publication-title: BMC Cancer – volume: 83 start-page: 829 year: 2023 end-page: 831 ident: bb0205 article-title: HK2: gatekeeping microglial activity by tuning glucose metabolism and mitochondrial functions publication-title: Mol. Cell – volume: 16 start-page: 724 year: 2020 end-page: 734 ident: bb0245 article-title: USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy publication-title: Autophagy – volume: 106 start-page: 14530 year: 2009 end-page: 14535 ident: bb0120 article-title: Deubiquitinating enzyme USP33/VDU1 is required for slit signaling in inhibiting breast cancer cell migration publication-title: Proc. Natl. Acad. Sci. USA – volume: 11 start-page: 963 year: 2015 end-page: 964 ident: bb0195 article-title: HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection publication-title: Autophagy – volume: 181 year: 2024 ident: bb0185 article-title: Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers publication-title: Biomed. Pharmacother. = Biomed. & Pharmacother. – volume: 8 year: 2022 ident: bb0100 article-title: PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling publication-title: Sci. Adv. – volume: 120 year: 2023 ident: bb0085 article-title: The moonlighting function of glycolytic enzyme enolase-1 promotes choline phospholipid metabolism and tumor cell proliferation publication-title: Proc. Natl. Acad. Sci. USA – volume: 71 start-page: 229 year: 1994 end-page: 249 ident: bb0180 article-title: Modulations of the epithelial phenotype during embryogenesis and cancer progression publication-title: Cancer Treat. Res. – volume: 85 start-page: 41 year: 2018 end-page: 49 ident: bb0150 article-title: Ovarian Cancer: a heterogeneous disease publication-title: Pathobiology – volume: 18 start-page: 2292 year: 2022 end-page: 2303 ident: bb0040 article-title: The role of ubiquitination and deubiquitination in tumor invasion and metastasis publication-title: Int. J. Biol. Sci. – volume: 9 start-page: 338 year: 2023 ident: bb0070 article-title: USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target publication-title: Cell Death Dis. – volume: 14 start-page: 1284853 year: 2023 ident: bb0080 article-title: Research progress on the mechanism of glycolysis in ovarian cancer publication-title: Front. Immunol. – volume: 47 start-page: 1368 year: 2023 end-page: 1380 ident: bb0115 article-title: USP33 enhances cell survival and stemness by deubiquitinating CTNNB1 in BXPC-3 and SW1990 cells publication-title: Cell Biol. Int. – volume: 38 start-page: 1 year: 2018 end-page: 11 ident: bb0090 article-title: How the Warburg effect supports aggressiveness and drug resistance of cancer cells? publication-title: Drug Resist. Updat. – volume: 23 year: 2022 ident: bb0025 article-title: Molecular biomarkers for the early detection of ovarian Cancer publication-title: Int. J. Mol. Sci. – volume: 37 start-page: 937 year: 2009 end-page: 953 ident: bb0160 article-title: The emerging complexity of protein ubiquitination publication-title: Biochem. Soc. Trans. – volume: 52 year: 2019 ident: bb0165 article-title: Reduced USP33 expression in gastric cancer decreases inhibitory effects of Slit2-Robo1 signalling on cell migration and EMT publication-title: Cell Prolif. – volume: 20 start-page: 1242 year: 2014 end-page: 1253 ident: bb0155 article-title: Ubiquitination in disease pathogenesis and treatment publication-title: Nat. Med. – volume: 20 start-page: 5208 year: 2024 end-page: 5222 ident: bb0065 article-title: Deubiquitinases in ovarian Cancer: role in drug resistance and tumor aggressiveness publication-title: Int. J. Biol. Sci. – volume: 13 start-page: 922 year: 2023 end-page: 935 ident: bb0135 article-title: Deubiquitinase USP33 promotes the glycolysis and growth of osteosarcoma by modifying PFKFB3 ubiquitination and degradation publication-title: Am. J. Cancer Res. – volume: 4 start-page: 287 year: 2009 end-page: 313 ident: bb0140 article-title: Ovarian cancer publication-title: Annu. Rev. Pathol. – volume: 13 start-page: 922 year: 2023 end-page: 935 ident: bb0230 article-title: Deubiquitinase USP33 promotes the glycolysis and growth of osteosarcoma by modifying PFKFB3 ubiquitination and degradation publication-title: Am. J. Cancer Res. – volume: 94 year: 2021 ident: bb0235 article-title: MYC as a target for cancer treatment publication-title: Cancer Treat. Rev. – volume: 91 start-page: 561 year: 2020 end-page: 575 ident: bb0005 article-title: Ovarian Cancer: an overview publication-title: Radiol. Technol. – volume: 43 start-page: 3170 year: 2024 end-page: 3183 ident: bb0130 article-title: USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2 publication-title: Oncogene – volume: 1866 year: 2023 ident: bb0050 article-title: Ubiquitination and deubiquitination: implications on cancer therapy publication-title: Biochim Biophys Acta Gene Regul Mech – volume: 50 start-page: 721 year: 2018 end-page: 733 ident: bb0170 article-title: Radiation enhances the epithelial- mesenchymal transition of A549 cells via miR3591-5p/USP33/PPM1A publication-title: Cell. Physiol. Biochem. – volume: 14 start-page: 1189953 year: 2023 ident: bb0215 article-title: Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion publication-title: Front. Immunol. – volume: 28 start-page: 427 year: 2021 end-page: 438 ident: bb0045 article-title: Ubiquitin signaling in cell cycle control and tumorigenesis publication-title: Cell Death Differ. – volume: 10 start-page: 3981 year: 2019 ident: bb0105 article-title: CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis publication-title: Nat. Commun. – volume: 11 year: 2024 ident: bb0055 article-title: Protein ubiquitination in ovarian cancer immunotherapy: the progress and therapeutic strategy publication-title: Genes Dis – volume: 4 start-page: 1239 year: 2023 end-page: 1257 ident: bb0145 article-title: Clinical and translational advances in ovarian cancer therapy publication-title: Nat. Can. – volume: 6 start-page: 240 year: 2021 ident: bb0190 article-title: Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc publication-title: Signal Transduct. Target. Ther. – volume: 21 start-page: 389 year: 2024 end-page: 400 ident: bb0010 article-title: Global epidemiology of epithelial ovarian cancer publication-title: Nat. Rev. Clin. Oncol. – volume: 72 start-page: 396 year: 2024 end-page: 410 ident: bb0200 article-title: HK2 in microglia and macrophages contribute to the development of neuropathic pain publication-title: Glia – volume: 42 start-page: 1008 year: 2022 end-page: 1027 ident: bb0210 article-title: A non-metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11-mediated CD133 stability publication-title: Cancer Communications (London, England) – volume: 22 start-page: 943 year: 2024 end-page: 956 ident: bb0060 article-title: Ubiquitin ligase TRIM22 inhibits ovarian Cancer malignancy via TCF4 degradation publication-title: Mol. Cancer Res. – volume: 292 year: 2022 ident: bb0095 article-title: Ubiquitination regulation of aerobic glycolysis in cancer publication-title: Life Sci. – volume: 4 start-page: 1239 year: 2023 end-page: 1257 ident: bb0020 article-title: Clinical and translational advances in ovarian cancer therapy publication-title: Nat. Can. – volume: 22 year: 2021 ident: bb0110 article-title: Advances in the development ubiquitin-specific peptidase (USP) inhibitors publication-title: Int. J. Mol. Sci. – volume: 245 year: 2023 ident: bb0075 article-title: Metabolic dependencies and targets in ovarian cancer publication-title: Pharmacol. Ther. – volume: 14 start-page: 362 year: 2023 ident: bb0125 article-title: USP33 promotes pancreatic cancer malignant phenotype through the regulation of TGFBR2/TGFβ signaling pathway publication-title: Cell Death Dis. – volume: 12 start-page: 181 year: 1994 end-page: 194 ident: bb0175 article-title: Oncogene-induced basement membrane invasiveness in human mammary epithelial cells publication-title: Clin. Exp. Metastasis – volume: 11 year: 2020 ident: bb0030 article-title: Immunotherapy for ovarian Cancer: adjuvant, combination, and neoadjuvant publication-title: Front. Immunol. – volume: 11 start-page: 145 year: 2020 ident: bb0220 article-title: Circular RNA circRNF20 promotes breast cancer tumorigenesis and Warburg effect through miR-487a/HIF-1α/HK2 publication-title: Cell Death Dis. – volume: 23 issue: 19 year: 2022 ident: 10.1016/j.bbagen.2025.130830_bb0025 article-title: Molecular biomarkers for the early detection of ovarian Cancer publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms231912041 – volume: 43 start-page: 3170 issue: 43 year: 2024 ident: 10.1016/j.bbagen.2025.130830_bb0130 article-title: USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2 publication-title: Oncogene doi: 10.1038/s41388-024-03151-9 – volume: 106 start-page: 14530 issue: 34 year: 2009 ident: 10.1016/j.bbagen.2025.130830_bb0120 article-title: Deubiquitinating enzyme USP33/VDU1 is required for slit signaling in inhibiting breast cancer cell migration publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0801262106 – volume: 6 start-page: 240 issue: 1 year: 2021 ident: 10.1016/j.bbagen.2025.130830_bb0190 article-title: Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc publication-title: Signal Transduct. Target. Ther. doi: 10.1038/s41392-021-00562-y – volume: 1866 issue: 4 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0050 article-title: Ubiquitination and deubiquitination: implications on cancer therapy publication-title: Biochim Biophys Acta Gene Regul Mech doi: 10.1016/j.bbagrm.2023.194979 – volume: 11 start-page: 963 issue: 6 year: 2015 ident: 10.1016/j.bbagen.2025.130830_bb0195 article-title: HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection publication-title: Autophagy doi: 10.1080/15548627.2015.1042195 – volume: 20 start-page: 1242 issue: 11 year: 2014 ident: 10.1016/j.bbagen.2025.130830_bb0155 article-title: Ubiquitination in disease pathogenesis and treatment publication-title: Nat. Med. doi: 10.1038/nm.3739 – volume: 14 start-page: 1189953 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0215 article-title: Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion publication-title: Front. Immunol. doi: 10.3389/fimmu.2023.1189953 – volume: 22 issue: 9 year: 2021 ident: 10.1016/j.bbagen.2025.130830_bb0110 article-title: Advances in the development ubiquitin-specific peptidase (USP) inhibitors publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms22094546 – volume: 11 start-page: 145 issue: 2 year: 2020 ident: 10.1016/j.bbagen.2025.130830_bb0220 article-title: Circular RNA circRNF20 promotes breast cancer tumorigenesis and Warburg effect through miR-487a/HIF-1α/HK2 publication-title: Cell Death Dis. doi: 10.1038/s41419-020-2336-0 – volume: 11 issue: 6 year: 2024 ident: 10.1016/j.bbagen.2025.130830_bb0055 article-title: Protein ubiquitination in ovarian cancer immunotherapy: the progress and therapeutic strategy publication-title: Genes Dis – volume: 24 start-page: 237 issue: 1 year: 2024 ident: 10.1016/j.bbagen.2025.130830_bb0225 article-title: USP14 exhibits high expression levels in hepatocellular carcinoma and plays a crucial role in promoting the growth of liver cancer cells through the HK2/AKT/P62 axis publication-title: BMC Cancer doi: 10.1186/s12885-024-12009-y – volume: 83 start-page: 829 issue: 6 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0205 article-title: HK2: gatekeeping microglial activity by tuning glucose metabolism and mitochondrial functions publication-title: Mol. Cell doi: 10.1016/j.molcel.2023.02.022 – volume: 71 start-page: 229 year: 1994 ident: 10.1016/j.bbagen.2025.130830_bb0180 article-title: Modulations of the epithelial phenotype during embryogenesis and cancer progression publication-title: Cancer Treat. Res. doi: 10.1007/978-1-4615-2592-9_12 – volume: 20 start-page: 5208 issue: 13 year: 2024 ident: 10.1016/j.bbagen.2025.130830_bb0065 article-title: Deubiquitinases in ovarian Cancer: role in drug resistance and tumor aggressiveness publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.100355 – volume: 120 issue: 15 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0085 article-title: The moonlighting function of glycolytic enzyme enolase-1 promotes choline phospholipid metabolism and tumor cell proliferation publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.2209435120 – volume: 4 start-page: 1239 issue: 9 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0020 article-title: Clinical and translational advances in ovarian cancer therapy publication-title: Nat. Can. – volume: 85 start-page: 41 issue: 1–2 year: 2018 ident: 10.1016/j.bbagen.2025.130830_bb0150 article-title: Ovarian Cancer: a heterogeneous disease publication-title: Pathobiology doi: 10.1159/000479006 – volume: 9 start-page: 338 issue: 1 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0070 article-title: USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target publication-title: Cell Death Dis. doi: 10.1038/s41420-023-01629-1 – volume: 50 start-page: 721 issue: 2 year: 2018 ident: 10.1016/j.bbagen.2025.130830_bb0170 article-title: Radiation enhances the epithelial- mesenchymal transition of A549 cells via miR3591-5p/USP33/PPM1A publication-title: Cell. Physiol. Biochem. doi: 10.1159/000494238 – volume: 18 start-page: 2292 issue: 6 year: 2022 ident: 10.1016/j.bbagen.2025.130830_bb0040 article-title: The role of ubiquitination and deubiquitination in tumor invasion and metastasis publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.69411 – volume: 20 start-page: 972 issue: 9 year: 2022 ident: 10.1016/j.bbagen.2025.130830_bb0015 article-title: NCCN guidelines® insights: ovarian Cancer, version 3.2022 publication-title: J. Natl. Compr. Cancer Netw. doi: 10.6004/jnccn.2022.0047 – volume: 8 issue: 38 year: 2022 ident: 10.1016/j.bbagen.2025.130830_bb0100 article-title: PKM2 promotes pulmonary fibrosis by stabilizing TGF-β1 receptor I and enhancing TGF-β1 signaling publication-title: Sci. Adv. doi: 10.1126/sciadv.abo0987 – volume: 42 start-page: 1008 issue: 10 year: 2022 ident: 10.1016/j.bbagen.2025.130830_bb0210 article-title: A non-metabolic function of hexokinase 2 in small cell lung cancer: promotes cancer cell stemness by increasing USP11-mediated CD133 stability publication-title: Cancer Communications (London, England) doi: 10.1002/cac2.12351 – volume: 181 year: 2024 ident: 10.1016/j.bbagen.2025.130830_bb0185 article-title: Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers publication-title: Biomed. Pharmacother. = Biomed. & Pharmacother. – volume: 94 year: 2021 ident: 10.1016/j.bbagen.2025.130830_bb0235 article-title: MYC as a target for cancer treatment publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2021.102154 – volume: 72 start-page: 396 issue: 2 year: 2024 ident: 10.1016/j.bbagen.2025.130830_bb0200 article-title: HK2 in microglia and macrophages contribute to the development of neuropathic pain publication-title: Glia doi: 10.1002/glia.24482 – volume: 245 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0075 article-title: Metabolic dependencies and targets in ovarian cancer publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2023.108413 – volume: 4 start-page: 1239 issue: 9 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0145 article-title: Clinical and translational advances in ovarian cancer therapy publication-title: Nat. Can. – volume: 13 start-page: 922 issue: 3 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0135 article-title: Deubiquitinase USP33 promotes the glycolysis and growth of osteosarcoma by modifying PFKFB3 ubiquitination and degradation publication-title: Am. J. Cancer Res. – volume: 11 year: 2020 ident: 10.1016/j.bbagen.2025.130830_bb0030 article-title: Immunotherapy for ovarian Cancer: adjuvant, combination, and neoadjuvant publication-title: Front. Immunol. doi: 10.3389/fimmu.2020.577869 – volume: 14 start-page: 1284853 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0080 article-title: Research progress on the mechanism of glycolysis in ovarian cancer publication-title: Front. Immunol. doi: 10.3389/fimmu.2023.1284853 – volume: 22 start-page: 943 issue: 10 year: 2024 ident: 10.1016/j.bbagen.2025.130830_bb0060 article-title: Ubiquitin ligase TRIM22 inhibits ovarian Cancer malignancy via TCF4 degradation publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-23-0962 – volume: 16 start-page: 724 issue: 4 year: 2020 ident: 10.1016/j.bbagen.2025.130830_bb0245 article-title: USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy publication-title: Autophagy doi: 10.1080/15548627.2019.1656957 – volume: 12 start-page: 181 issue: 3 year: 1994 ident: 10.1016/j.bbagen.2025.130830_bb0175 article-title: Oncogene-induced basement membrane invasiveness in human mammary epithelial cells publication-title: Clin. Exp. Metastasis doi: 10.1007/BF01753886 – volume: 21 start-page: 389 issue: 5 year: 2024 ident: 10.1016/j.bbagen.2025.130830_bb0010 article-title: Global epidemiology of epithelial ovarian cancer publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-024-00881-3 – volume: 47 start-page: 1368 issue: 8 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0115 article-title: USP33 enhances cell survival and stemness by deubiquitinating CTNNB1 in BXPC-3 and SW1990 cells publication-title: Cell Biol. Int. doi: 10.1002/cbin.12024 – volume: 4 start-page: 287 year: 2009 ident: 10.1016/j.bbagen.2025.130830_bb0140 article-title: Ovarian cancer publication-title: Annu. Rev. Pathol. doi: 10.1146/annurev.pathol.4.110807.092246 – volume: 91 start-page: 561 issue: 6 year: 2020 ident: 10.1016/j.bbagen.2025.130830_bb0005 article-title: Ovarian Cancer: an overview publication-title: Radiol. Technol. – volume: 33 start-page: 235 issue: 3 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0240 article-title: MYC: a complex problem publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2022.07.006 – volume: 14 start-page: 362 issue: 6 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0125 article-title: USP33 promotes pancreatic cancer malignant phenotype through the regulation of TGFBR2/TGFβ signaling pathway publication-title: Cell Death Dis. doi: 10.1038/s41419-023-05871-4 – volume: 10 start-page: 3981 issue: 1 year: 2019 ident: 10.1016/j.bbagen.2025.130830_bb0105 article-title: CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis publication-title: Nat. Commun. doi: 10.1038/s41467-019-11662-3 – volume: 20 start-page: 1242 issue: 11 year: 2014 ident: 10.1016/j.bbagen.2025.130830_bb0035 article-title: Ubiquitination in disease pathogenesis and treatment publication-title: Nat. Med. doi: 10.1038/nm.3739 – volume: 292 year: 2022 ident: 10.1016/j.bbagen.2025.130830_bb0095 article-title: Ubiquitination regulation of aerobic glycolysis in cancer publication-title: Life Sci. doi: 10.1016/j.lfs.2022.120322 – volume: 28 start-page: 427 issue: 2 year: 2021 ident: 10.1016/j.bbagen.2025.130830_bb0045 article-title: Ubiquitin signaling in cell cycle control and tumorigenesis publication-title: Cell Death Differ. doi: 10.1038/s41418-020-00648-0 – volume: 37 start-page: 937 issue: Pt 5 year: 2009 ident: 10.1016/j.bbagen.2025.130830_bb0160 article-title: The emerging complexity of protein ubiquitination publication-title: Biochem. Soc. Trans. doi: 10.1042/BST0370937 – volume: 13 start-page: 922 issue: 3 year: 2023 ident: 10.1016/j.bbagen.2025.130830_bb0230 article-title: Deubiquitinase USP33 promotes the glycolysis and growth of osteosarcoma by modifying PFKFB3 ubiquitination and degradation publication-title: Am. J. Cancer Res. – volume: 38 start-page: 1 year: 2018 ident: 10.1016/j.bbagen.2025.130830_bb0090 article-title: How the Warburg effect supports aggressiveness and drug resistance of cancer cells? publication-title: Drug Resist. Updat. doi: 10.1016/j.drup.2018.03.001 – volume: 52 issue: 3 year: 2019 ident: 10.1016/j.bbagen.2025.130830_bb0165 article-title: Reduced USP33 expression in gastric cancer decreases inhibitory effects of Slit2-Robo1 signalling on cell migration and EMT publication-title: Cell Prolif. doi: 10.1111/cpr.12606 |
| SSID | ssj0000595 |
| Score | 2.4690816 |
| Snippet | Ovarian cancer (OC) is one of the most lethal gynecological malignancies, characterized by late-stage presentation, high recurrence rates, and a lack of... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 130830 |
| SubjectTerms | Apoptosis C-Myc Cell Line, Tumor Cell Movement Cell Proliferation Deubiquitination Disease Progression Female Gene Expression Regulation, Neoplastic Glycolysis Humans Metabolic reprogramming Ovarian cancer Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Protein Stability Proto-Oncogene Proteins c-myc - genetics Proto-Oncogene Proteins c-myc - metabolism SP33 Ubiquitin Thiolesterase - genetics Ubiquitin Thiolesterase - metabolism |
| Title | USP33-mediated stabilization of c-Myc drives glycolytic reprogramming and promotes ovarian cancer progression |
| URI | https://dx.doi.org/10.1016/j.bbagen.2025.130830 https://www.ncbi.nlm.nih.gov/pubmed/40532745 https://www.proquest.com/docview/3222355399 |
| Volume | 1869 |
| WOSCitedRecordID | wos001520808800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect (Freedom Collection) customDbUrl: eissn: 1872-8006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000595 issn: 0304-4165 databaseCode: AIEXJ dateStart: 19950118 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9swFBZpu7G-jK27ZZeiwd6CQ2xJkf1YQsc2WCmsBW8vRrLlxqG1Q240_U37kTuSLCde6bY-7MUkQhaKzpejT0fngtCHIKNAWjPhBTRTHhXhwBPaIpbLjA8V9TMuqSk2wU9OwjiOTjudny4WZnXJyzK8vo6m_1XU0AbC1qGz9xB3Myg0wGcQOjxB7PD8J8GffzslxDMRIZpNAvvT_q83DTVMva_rtJfNTL7Zi8s1IGFtEznXvlpXLm5xalz1dFbaFZyoQRGkGiIz69Nl83m07oSLKh0XOv1ATy16sqis1UTofB2i7xJc9-ZLqW0_DZcfjZ3mmxTNHvFjLIwN9_tSbTVZvRQXopJVYxoyVYlNI-Cv3odrM0bAGie6JnxrQD1gh6ytmm0dlxqE0Zamhb03tDc6tzYBa4-Y9KWEjjrHbcD6m-7tnNu_7YWNh6JzfpskdpREj5LYUXbQXsBZBDp07-jzcfxls_MzU-Wn-SkuVNP4E96ezV1U6K6jjqE8Z0_Q4_qsgo8sxp6ijioP0ENbvXR9gB6NXLHAZ-iqjTrcQh2ucmxQhy3q8AZ1uIU6DKjDDnW4Rh22qMNbqHuOzj8en40-eXUlDy8lPll4ofBVRgJJWEoCkUkmBimLAsFZJoeKZDpOKSdp6Ochh7455ZH0aR7kQGgJfCMv0G5ZleoVwgqOAEP9ei4oHUoZscFARaEMVR7B6SftIs8tajK1CVuSPwmzi7hb-aQmnZZMJgCnv7z53gkqgdXWF22iVNVynujbS-DxwP276KWVYDMXqkuxcMpe33Oeb9D-5m_zFu0uZkv1Dj1IV4tiPjtEOzwOD2s8_gIyyrz8 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=USP33-mediated+stabilization+of+c-Myc+drives+glycolytic+reprogramming+and+promotes+ovarian+cancer+progression&rft.jtitle=Biochimica+et+biophysica+acta.+General+subjects&rft.au=Chen%2C+Dejia&rft.au=Zhao%2C+Yue&rft.au=Zhang%2C+Xiaobo&rft.au=Shi%2C+Xiaocheng&rft.date=2025-08-01&rft.issn=0304-4165&rft.volume=1869&rft.issue=9&rft.spage=130830&rft_id=info:doi/10.1016%2Fj.bbagen.2025.130830&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_bbagen_2025_130830 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-4165&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-4165&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-4165&client=summon |